Lending Market Alert: GLSI
Greenwich LifeSciences (GLSI) is currently flashing a high-conviction signal for short-selling analysts. As of the latest data from IBorrowDesk, the borrow fee for GLSI has reached 25.2% APR. This elevated cost, combined with a constrained supply of only 65,000 shares available for lending, suggests that institutional and retail shorts are facing significant friction in maintaining or opening new positions.
Why This Matters
When borrow fees reach these levels, it typically indicates that the supply of lendable shares is drying up, often a precursor to a potential short squeeze if positive catalysts emerge. While this data is specific to the Interactive Brokers ecosystem, it serves as a reliable proxy for broader market sentiment and liquidity constraints on the stock. Traders should monitor for further contraction in share availability, which could exacerbate the cost-to-borrow pressure.
Key Takeaways
- Borrow fee is currently 25.2% APR.
- Share availability is extremely tight at 65,000 shares.
- High borrow costs indicate significant demand from short sellers.
The Bottom Line
GLSI is currently one of the most expensive stocks to borrow in its sector, signaling that the short side is crowded and liquidity is becoming increasingly scarce.
Signal data sourced from IBorrowDesk. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.